H.C. Wainwright analyst Joseph Pantginis downgraded Tempest Therapeutics (NASDAQ: TPST) from Buy to Neutral.The analyst comments "Fundamentals of strong randomized ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE